Viral Antigen Ingredients TRIZ Cases
- Single B-Cell IgG Cloning for Homogeneous Epitope-Specific Antibodies
Cloning functional heavy and light chains from a single B-cell enables homogeneous antibodies with precise epitope specificity, avidity, and affinity.
- Viral Vector Infectivity Verification Using Flow Cytometry
Ion-exchange purification plus antibody-based flow cytometry verifies infectious viral vectors in under 3 days, cutting vaccine manufacturing time and cost.
- Recombinant MDV1 Vaccine Vector for Interference-Free Poultry Immunity
Using rMDV1 at the MDV086.6 locus avoids HVT vaccine interference while maintaining stable antigen expression and extended poultry immunity.
- Modified HLA-Binding Pocket for Stronger Tumor Epitope Presentation
By altering HLA pocket residues, this case boosts tumor epitope binding and stabilizes antigen presentation for stronger T cell responses.
- Single B-Cell IgG Screening for Homogeneous Epitope Binding
Cloning heavy and light chains from single B-cells and screening specificity, avidity, and affinity helps produce homogeneous IgG.
- Immune Response Assay Composition Using Non-Reducing Sugars
Adding non-reducing sugars such as trehalose during antigen incubation improves cell-mediated assay sensitivity while preserving storage stability.
- CMV-Vector HBV Vaccine for Chronic Infection Immunotherapy
CMV vectors expressing episensus HBV antigens sustain CD8+ T cell responses to target chronic infection across genotype diversity.
- DNA-mRNA Prime-Boost Immunogens for Durable HIV Immunity
Combining DNA priming with LNP-delivered mRNA boosting strengthens durable CD4+, CD8+, and antibody responses against HIV.
- Multivalent HSV mRNA Vaccines Without Latent Infection Risk
Modified HSV antigen mRNAs in lipid nanoparticles trigger neutralizing antibodies and CD8+ T cells without live-virus latency risk.
- Herpes Zoster mRNA Vaccine With gE Variants for Higher Immunogenicity
VZV gE variant mRNA in lipid nanoparticles boosts herpes zoster vaccine immunogenicity while avoiding limits of live and protein vaccines.
- HIV-1 Protein Activation of Latent Memory CD4+ T Cell Reservoirs
Allogenic or autologous HIV-1 proteins activate latent memory CD4+ T cells, helping reduce reservoir cells and prevent viral rebound.
- Recombinant Yeast Vaccine Platform With VLP Assembly and DIVA Capability
Recombinant Kluyveromyces marxianus enables stable antigen expression, VLP assembly, and DIVA-ready whole yeast vaccines for PRV and AHSV.
- Lyophilized HPV Vaccine Formulation for Refrigeration-Free Stability
Lyophilized HPV formulations with disaccharides and volatile salts preserve immunogenicity for storage and transport without refrigeration.
- Flt3L mRNA Immune Priming Without Protein Side Effects
Using mRNA to encode Flt3L boosts dendritic, B-cell, and T-cell responses while avoiding anaphylaxis and costly protein production.
- Enhanced APC Therapy for HLA-Agnostic HPV Cancer Targeting
Modified APCs loaded with HPV antigens activate T cells across diverse HLA types and help reduce tumor burden in HPV-associated cancers.
- Enhanced APC Formulations for HLA-Agnostic T Cell Activation
Cryopreserved enhanced APC formulations preserve viability for long-term storage while enabling HLA-agnostic T cell activation against HPV antigens.